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ABSTRACT: The decline in Testosterone (T) levels in the ageing 
male - known as andropause or late-onset hypogonadism - may be 
responsible for several aspects of quality of life decline in older men: 
erectile dysfunction, impaired libido, decreased strength and energy, 
sarcopenia, osteopenia, fatigue and even depression in some cases. 
Many of these signs and symptoms represent the same alterations that 
are usually attributed to the process of ageing. When some individual 
presents with such symptoms, hypogonadism should be suspected, 
and serum T level should be evaluated. Men who are symptomatic 
and present low levels of serum Testosterone (generally below 300 
ng/ml) are candidates for T replacement therapy. Current evidence 
shows that, when correctly selected, patients receiving T replacement 
may benefit from improvement in libido, erectile function, overall 
and sexual related quality of life, bone density and muscle mass. 
Conversely, patients with physiological circulating levels of T who 
receive hormone, aiming at supraphysiologic levels, may face severe 
side effects, including testicular atrophy and behavioral changes. Of 
note, T replacement, regardless of age and pre-therapy levels, leads 
to fertility impairment which can be transient or persistent. Direct 
testosterone replacement should not be indicated in men who wish to 
conceive children, although other options are available. The effect of 
Testosterone replacement on prostate cancer and on cardiovascular 
risk is still controversial; hypogonadal men known to have prostate 
cancer or high cardiovascular risk should be examined individually 
to have their risks stratified and mitigated.  
Keywords: Androgens; Testosterone; Male; Ageing; Hormone 
replacement therapy.
RESUMO: A queda dos níveis séricos de testosterona em homens 
de idade avançada – conhecida como andropausa ou hipogonadismo 
tardio – pode ser responsável por vários aspectos no declínio da 
qualidade de vida de homens idosos: disfunção erétil, diminuição 
da libido, redução de força física e energia, sarcopenia, osteopenia, 
fadiga e até depressão. Muitos de tais sinais e sintomas representam 
as mesmas alterações habitualmente atribuídas ao processo de 
envelhecimento. Quando um paciente se apresenta com esses 
sintomas, deve-se suspeitar do diagnóstico de hipogonadismo, sendo 
recomendada a dosagem de níveis séricos de testosterona. Homens 
sintomáticos apresentando níveis séricos de Testosterona total abaixo 
de 300 ng/ml são candidatos a terapia de reposição de testosterona. 
Evidências atuais indicam que, quando selecionados corretamente, 
pacientes que recebem reposição de testosterona se beneficiam de 
melhora na libido, na função erétil, em qualidade de vida nos aspectos 
gerais e nos quesitos ligados à vida sexual, bem como na densidade 
óssea e no ganho de massa muscular. No entanto, pacientes com níveis 
fisiológicos de Testosterona que recebem hormônio exógeno, visando 
atingir níveis supra-fisiológicos, podem enfrentar efeitos colaterais 
graves tais como atrofia testicular e alterações comportamentais, 
como agressividade exacerbada. Deve-se notar que a reposição 
de testosterona, independentemente da idade e de níveis séricos 
hormonais pré-tratamento, leva a prejuízo na fertilidade masculina, 
um fenômeno que pode ser transitório ou persistente. Em pacientes 
que possuem desejo reprodutivo, a reposição direta de testosterona 
não deve ser indicada, devendo-se levar em consideração outras 
opções como o citrato de clomifeno, de ação central. O efeito da 
reposição de testosterona no risco de câncer de próstata e no risco 
cardiovascular é ainda controverso; homens com hipogonadismo 
que sabidamente possuem câncer de próstata ou alto risco vascular 
devem ser examinados individualmente de modo a terem seus riscos 
estratificados e mitigados.
Descritores: Androgênios; Testosterona; Masculino; Envelhecimento; 
Terapia de reposição hormonal.
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INTRODUCTION
Providing higher quality of life to an ever-ageing population is one of the current goals in 
contemporary Medicine. Maintenance of physical, mental 
and sexual function are pursued by both patients and 
practitioners and challenged by several factors in the elderly 
population. Among these, the decline in Testosterone (T) 
levels seen in the ageing male - known as andropause, 
or late-onset hypogonadism - may play a critical role in 
several domains, from physical to psychological1,2. The 
Hypogonadism in Males Study estimated that up to 39% 
of men aged 45 years or older may have hypogonadism3. 
Of note, several symptoms of male hypogonadism have 
significant overlap with those usually attributed to the 
process of ageing, including sarcopenia, osteopenia, 
fatigue, decreased libido and sexual function and mental 
manifestations such as depression2,4. Hence, a thorough 
evaluation is needed when the diagnosis of hypogonadism 
is suspected: neither isolated symptoms nor isolated low 
levels of serum testosterone are sufficient to diagnose 
this condition. Rather, the concomitant presence of 
testosterone levels below 3.2 ng per milliliter associated 
with at least three sexual symptoms define the condition 
of late-onset male hypogonadism5. Accordingly, indication 
for testosterone replace therapy relies on the presence of 
typical symptoms together with low serum T levels6. As 
per the Endocrine Society guidelines, physicians should 
measure T levels of patients with signs and symptoms such 
as reduced libido, reduced muscle mass, depressed mood, 
decreased energy, osteoporosis, gynecomastia, shrinking 
testes, infertility, poor concentration, sleep disturbances, 
increased body fat and anemia7 (Table 1).
Table 1. Signs and symptoms which should raise suspicion for 
hypogonadism and elicit hormonal investigation 
Reduced libido Erectile Dysfunction
Reduced muscle mass Osteopenia/osteoporosis
Increased body fat Anemia
Gynecomastia Shrinking testes
Decreased energy Fatigue
Depressed Mood Poor concentration
Sleep disturbance Infertility 
It has been once unclear, however, if symptoms 
usually associated with hypogonadism could be correctly 
attributed to the effect of low circulating hormone levels. 
It has been speculated that sexual inactivity could lead 
to reduced testicular function and work as a cause and 
not consequence of this phenomenon6. Evidence for 
this question has arisen from clinical trials of androgen 
replacement investigating sexual function of hypogonadal 
men after Testosterone Therapy (TTh)8. Likewise, the effect 
of TTh has been studied on several domains including 
quality of life, mental health and body mass. In this 
review, we will outline the current evidence of the effect of 
Androgen Replacement Therapy (ART) on several aspects 
of male hypogonadism, along with implications of such 
treatment on concerning events such as Prostate Cancer 
(PCa) and cardiovascular risk. 
Erectile function
Several prospective placebo-controlled randomized 
clinical trials have been conducted in order to investigate the 
role of TTh on sexual function among hypogonadal men. 
Although results were not entirely homogeneous between 
studies, it must be noted that several factors - including 
definition of hypogonadism, baseline serum T among 
participants and presence of comorbidities may influence 
the outcomes of trials. Overall, as per demonstrated in a 
several meta-analyses, ART with Testosterone appears to 
be effective in improving erectile dysfunction, as measured 
by the International Index of Erectile Function (IIEF), 
with greater effect in patients with lower baseline T levels 
and more modest effect among patients with clinical 
comorbidities such as diabetes8-11. However, when patients 
receiving TTh include eugonadal men, this therapy does 
not appear to provide benefit on sexual function12.
Allan et al.13 showed that Testosterone replacement 
with a transdermal patch increased libido, yet with no 
effect of erectile function. Conversely, in a trial performed 
by Chiang et al.14, TTh resulted in erectile function 
improvement with no changes in libido. In accordance 
with the latter, Giltay et al.15 demonstrated a 3-point 
improvement in the IIEF scale in hypogonadal men 
receiving TTh, with the most effective results in patients 
with lowest baseline T values. The most recent evidence 
indicates that, when indicated to men correctly diagnosed 
with hypogonadism, TTh presents overall positive results 
on erectile function8. However, the improvement on erectile 
function attributed to TTh alone may be modest. In cases 
of severe erectile dysfunction, this treatment may not be 
enough to satisfy an individual’s desire for improvement. 
Likewise, when other factors such as obesity and diabetes 
are present, vascular and neurogenic mechanisms causing 
erectile dysfunction are not addressed by TTh. Although 
ART may be effective in improving erectile function in 
hypogonadal men, physicians must carefully select patients 
who may benefit from this therapy and be aware of its 
limitations. 
Quality of life and mental health
Several randomized controlled trials have been 
performed to investigate if TTh would lead to Quality 
of Life (QoL) improvement in hypogonadal men. A 
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recent meta-analysis of randomized controlled trials has 
demonstrated that Testosterone replacement in men with 
late onset hypogonadism can have significant impact on 
QoL in several domains including psychological, somatic 
and sexual aspects16. However, individual studies have 
shown different results in select domains and populations. 
Legros et al.17 randomized 322 subjects for placebo or an 
oral dose of 80, 160 or 240 mg of Testosterone undecanoate 
in a multicentric study. Improvement in overall QoL 
was significant but similar between placebo and TTh; 
conversely, in sexual-related QoL, T replacement with 160 
mg showed significant improvement over placebo or other 
doses. Srinivas-Shankar et al.18, in a study with 274 patients 
randomized for placebo or transdermal T replacement of 
50 mg per day have demonstrated significant improvement 
in overall, sexual and somatic QoL. Of note, patients 
who presented most significant improvement were elder 
and more fragile individuals. Ho et al randomized 120 
for placebo or intramuscular testosterone undecanoate 
injections of 1000 mg19. They have found that patients 
receiving T injections presented significant improvement 
on overall QoL, psychological and somatic aspects, with a 
non-significant improvement in the sexual domain. Taken 
together, the current evidence accumulated, as analyzed in 
a meta-analysis, suggests that TTh can in fact lead to QoL 
improvement in hypogonadal men. Furthermore, it appears 
that T replacement in men with late onset hypogonadism 
may have a beneficial effect on reducing depression and 
enhancing cognitive performance among symptomatic 
patients20. It must be noted, however, that such effects 
have only been demonstrated for hypogonadal men with 
document levels of serum T below normality. 
Sarcopenia and osteoporosis
The role of T on muscle anabolism is one of the first 
documented effects of this hormone. The indiscriminate use 
of exogenous T in eugonadal men with this purpose often 
leads to supraphysiologic levels of T and corresponding 
adverse effects, including mental and behavioral changes21. 
However, in symptomatic individuals with hypogonadism, 
TTh is indicated to restore skeletal muscle mass. It has 
been consistently demonstrated that T replacement in 
hypogonadal men can lead to increased muscle mass, 
increase in bone density, increased strength and a decrease 
in fat mass22-24.
Diagnosis and treatment
Patients presenting with symptoms suggestive of 
hypogonadism, in special older men with a suspicion of 
late onset hypogonadism, should have their hormonal 
investigation performed. These symptoms include reduced 
libido, fatigue, sarcopenia, depressed mood, increased body 
fat among others (Table 1). The diagnosis of hypogonadism 
consists in the presence of symptoms associated with serum 
testosterone below a given cut-off, which may vary from 
230 ng/dl to 300 ng/dl according to different societies 
(Table 2). Complementary investigation should also include 
Follicle stimulating hormone and Luteinizing hormone. 
Table 2. Diagnostic reference values for hypogonadism, 
considering the limit below which patients will usually benefit 
from testosterone therapy
Endocrine Society
Total testosterone below 280-300 ng/dl
Free testosterone below 5-9 ng/dl
*excluding evaluation during acute or 
subacute illness
European Association 
of Urology, American 
Society of Andrology
Total testosterone below 230 ng/dl
If symptoms are enough to impair patient’s quality 
of life, and after discussion of potential benefits and 
adverse effects, testosterone replacement therapy may 
be offered to patients. Options for testosterone therapy 
include intramuscular, transdermal or buccal presentations 
(Table 3). Each method is associated with a different profile 
of adverse effects and has with a particular posology. 
Intramuscular injections are associated with relatively few 
adverse effects, and require injections twice a month. By 
contrast, a transdermal gel will not require injections, but 
will demand daily applications and is associated with a 
risk of transmission of hormone to partners and children. 
Table 3. Treatment options for hypogonadism 
Formulation Dose Potential adverse effects 
Intramuscular injection 75-100 mg weekly or 150-200 mg every 2 weeks
Transdermal gel 5-10 g applied daily (5-10 mg testosterone systemically absorbed) Gel transference to partner or children
Transdermal patches (non-scrotal) 2.5-7.5 mg applied nightly Skin reaction
Long-lasting intramuscular injection 750 mg every 10 weeks Pulmonary oil microembolization
Buccal tablets 30 mg tablet applied to the buccal mucosa every 12 h Inflammation of the gums
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Potential adverse effects
Infertility
The use of exogenous T is well known to have 
negative effects on male fertility. The elevated serum T 
resulting from exogenous intake leads to a negative feedback 
inhibition of the hypothalamic pituitary gonadal axis. Such 
inhibition results in suppression of spermatogenesis, low 
intratesticular T levels and ultimately oligospermia or 
azoospermia and testicular atrophy25. Although this effect 
can be reversible in up to 50% of patients after 6 months 
of therapy cessation, up to 10% of patients may remain 
persistently azoospermic after TTh26. Hence, exogenous 
T replacement must be discouraged in hypogonadal men 
with intention to conceive in the future. Instead, such 
patients should be offered alternative treatments aiming 
at upregulation of the hypothalamic pituitary axis and 
ultimately elevating endogenous T production. Among 
options of such a treatment there is Clomiphene citrate, 
a selective estrogen receptor modulator, which acts in 
the hypothalamus and pituitary opposing the inhibitory 
effect of estrogens on gonadotropin release. As a result, 
gonadotropin levels rise and T production by the testes 
is stimulated27. Other options include human Chorionic 
Gonadotropin (hCG) - which stimulates endogenous T 
production by Leydig cells - and aromatase inhibitors, such 
as anastrozole, which block peripheral conversion of T to 
estrogen and are most effective in obese subjects27.
Prostate cancer
Current understanding of the relationship between 
Testosterone and Prostate Cancer does not follow a linear 
correlation. Rather, the saturation model proposed by 
Morgentaler and Traish predicts that changes in serum 
T concentration below the point of maximal androgen-
receptor binding will lead to clinically significant 
modifications in prostate growth and prostate cancer28. 
This is the case for androgen deprivation therapy, in 
which levels are aimed at 30 ng/dL or lower. However, in 
patients with levels of serum T above the point of maximal 
androgen-receptor binding, oscillations of serum T do 
not correlate to clinically significant changes in prostate 
growth or cancer. This theory explains the observation that 
endogenous levels of T do not increase the risk of Prostate 
Cancer29,30. Current evidence does not show an increased 
risk for Prostate Cancer in hypogonadal men receiving 
androgen replacement therapy as compared to age-paired 
controls or to subjects receiving placebo31,32. Furthermore, 
the previous use of T replacement does not increase Prostate 
Cancer severity in patients presenting this diagnosis33. The 
use of Testosterone replacement in hypogonadal men with 
treated prostate cancer may be considered, although this 
is still a controversial subject34. Current evidence suggests 
that hypogonadal men with low or moderate risk disease 
receiving T replacement after radical prostatectomy do not 
present increased risk of disease recurrence35. Yet, series of 
patients receiving T Therapy after surgery or radiotherapy 
are small and evidence is limited. Although T therapy may 
be considered for hypogonadal patients after treatment for 
Prostate Cancer, it should be restricted to patients with 
low or moderate risk disease and undetectable or stable 
Prostate-Specific Antigen (PSA) levels. Patients should be 
informed that the current level of evidence is insufficient to 
definitively exclude the risk of disease recurrence, although 
disease recurrence may or may not be related to this therapy. 
Cardiovascular risk
The potential risks and benefits of T for 
cardiovascular effects have long been unknown and 
controversial. Different studies have elicited opposing 
results regarding the risk of cardiovascular events following 
testosterone replacement. A recent systematic review 
investigated such contrasting results36. Morgentaler et al 
demonstrated that, while 4 studies have shown an increased 
for cardiovascular events after T prescription, several 
dozen studies have shown, conversely, a beneficial effect 
of normal testosterone levels on cardiac risk and mortality. 
These authors have demonstrated, according to their review 
of the literature, that current evidence suggests that serum T 
concentration is inversely related to incidence and severity 
of coronary artery disease, as well as with mortality (level of 
evidence IIa). Also of note, a recent meta-analysis including 
75 randomized controlled trials with over 5,000 patients 
did not demonstrate an overall increase in cardiovascular 
risk after T replacement; furthermore, in patients with 
metabolic derangements, T therapy was associated with a 
protective effect on cardiovascular risk37. As per most recent 
evidence, it appears that testosterone replacement in older 
men with hypogonadism could provide cardiovascular 
protection and carries a lower risk for cardiovascular 
events38. In a retrospective cohort including over 40,000 
men, Cheetham et al.38 showed that hypogonadal men 
who received testosterone presented lower risk of stroke 
and myocardial infarction as compared to those who 
never received T reposition. However, this effect may be 
significant only when hormone levels reach normality. 
It appears that T replacement could potentially provide 
cardiovascular benefit for selected patients; however, this 
statement is yet to be confirmed. Currently, evidence for the 
use of T in men at high cardiovascular risk is not considered 
to be enough to safely indicate hormone reposition in such 
patients38. Men at low or intermediate risk are considered 
safe candidates for T therapy; however, this should not 
be indicated in men with a recent myocardial infarction, 
revascularization, poorly controlled heart failure, and stroke 
within the previous 6 months39.
CONCLUSIONS
Testosterone replacement in hypogonadal men 
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can lead to several benefits, including recovery of sexual 
function, libido, muscle mass and overall quality of life. 
However, diagnosis of this condition and indication for 
therapy must be strict and follow guidelines. The use 
of Testosterone in asymptomatic men or in subjects 
with normal levels of serum Testosterone should not be 
encouraged by physicians.
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